Is SABR Cost-Effective in Oligometastatic Cancer? An Economic Analysis of the SABR-COMET Randomized Trial
Xiaotao Qu, Yujie Chen, Gregory S. Zaric, Suresh Senan, Robert Olson, Stephen Harrow, Ava John‐Baptiste, Stewart Gaede, Liam Mulroy, Devin Schellenberg, Sashendra Senthi, Anand Swaminath, Neil Kopek, Mitchell Liu, Andrew Warner, George Rodrigues, David A. Palma, Alexander V. Louie
Topics & Concepts
SABR volatility modelMedicineRandomized controlled trialQuality-adjusted life yearCost-effectiveness analysisInternal medicineCost effectivenessEconometricsMathematicsVolatility (finance)Risk analysis (engineering)Stochastic volatilityManagement of metastatic bone diseaseHealth Systems, Economic Evaluations, Quality of LifeEconomic and Financial Impacts of Cancer